Xavier G. C.
- Country
- Spain
- Department
- Servicio de Otorrinolaringología
Research Overview
- Long‑Term Safety and Tolerability of Subcutaneous Itepekimab in Adults with Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps: Double‑Blind Extension Study
- Evaluation of AZD9574 Monotherapy and Combination Therapy in Advanced Solid Malignancies: A Phase I/IIa Study
- Phase II Study on Sacituzumab Govitecan, Loperamide, and Filgrastim in Metastatic Triple-Negative and Luminal Breast Cancer Patients
Data & Insights
Has run more than one trial at 158 of 445 partner sites.
Specializations
Breast Cancer Specialization
This investigator demonstrates significant expertise in treating various forms of breast cancer, with particular focus on specific molecular subtypes and advanced disease states.
- HER2-positive breast cancer treatment
- Hormone receptor-positive (HR+) breast cancer management
- Triple-negative breast cancer (TNBC) interventions
- Advanced and metastatic breast cancer therapy
The investigator's work encompasses both early-stage and advanced breast cancer treatments.
Molecular Targeted Therapies
The investigator specializes in targeted therapeutic approaches for various genetic and molecular markers in cancer treatment.
- BRCA mutation-targeted treatments
- HER2-targeted therapy applications
- Hormone receptor targeting strategies
- IDH-mutant cancer treatment
Their work includes novel approaches in precision medicine for various genetic alterations.
Advanced Oncology
The investigator focuses on treating advanced solid malignancies across multiple cancer types.
- Ovarian cancer treatment
- Prostate cancer therapy
- Pancreatic cancer interventions
- Endometrial cancer management
Their expertise extends to various combination therapy approaches for advanced cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.